These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
165 related items for PubMed ID: 3859248
21. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Khayat D, Lokiec F, Bizzari JP, Weil M, Meeus L, Sellami M, Rouesse J, Banzet P, Jacquillat C. Cancer Res; 1987 Dec 15; 47(24 Pt 1):6782-5. PubMed ID: 3677107 [Abstract] [Full Text] [Related]
22. The effect of bestatin on patients with acute and chronic leukemia and malignant lymphoma. Arimori S, Nagao T, Shimizu Y, Watanabe K, Komatsuda M. Tokai J Exp Clin Med; 1980 Jan 15; 5(1):63-71. PubMed ID: 6930119 [Abstract] [Full Text] [Related]
26. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group. Imamura Y, Takagi T, Yawata Y, Nishinarita S, Kosaka M, Mikuni C, Takatsuki K, Sezaki T, Mori M, Tsuchiya J. Int J Hematol; 1994 Feb 15; 59(2):113-23. PubMed ID: 8018904 [Abstract] [Full Text] [Related]
28. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study. Ahmann FR, Meyskens FL, Jones SE, Bukowski RM, Saiers JH, Ryan DH, Costanzi J, Vaughn CB, Coltman CA. Cancer Treat Rep; 1983 Feb 15; 67(7-8):697-700. PubMed ID: 6688199 [Abstract] [Full Text] [Related]
29. [Administration of vindesine sulfate for the treatment of malignant hematological tumors]. Ueda T, Masaoka T, Shibata H, Kubota Y, Saigo K, Kusakabe H, Takubo T, Nakamura H, Yoshitake J, Ishigami S. Gan To Kagaku Ryoho; 1982 Feb 15; 9(2):306-15. PubMed ID: 6764103 [Abstract] [Full Text] [Related]
30. Antitumor activity and toxicity of methyl 6-[3-(2-chloroethyl)- 3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in experimental animals. Fujimoto S, Tashiro T, Ogawa M. Gan; 1984 Oct 15; 75(10):937-46. PubMed ID: 6510639 [Abstract] [Full Text] [Related]
31. [Therapeutic effect of ranimustine(MCNU) on myeloproliferative disorder and chronic myelomonocytic leukemia]. Maeda S, Okabe M, Kurosawa M, Kunieda Y, Imamura M, Morioka M, Sakurada K, Miyazaki T, Sukegawa M. Gan To Kagaku Ryoho; 1991 Feb 15; 18(2):251-8. PubMed ID: 1992919 [Abstract] [Full Text] [Related]
32. [Phase II study of mitoxantrone for hematologic malignancies]. Ueoka H, Ueno K, Yamane T, Toyoda K, Endo H, Nishihara R, Takahashi I, Ohnoshi T, Kitajima K, Kimura I. Gan To Kagaku Ryoho; 1983 Nov 15; 10(11):2399-402. PubMed ID: 6639101 [Abstract] [Full Text] [Related]
37. [Phase II study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies]. Sampi K, Honda T, Hayashi Y, Hattori M. Gan To Kagaku Ryoho; 1983 Jun 15; 10(6):1538-9. PubMed ID: 6347083 [Abstract] [Full Text] [Related]
39. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies]. Kimura K, Yamada K, Uzuka Y, Masaoka T, Hirano M, Ohno R, Ogawa M. Gan To Kagaku Ryoho; 1989 Jan 15; 16(1):123-30. PubMed ID: 2643392 [Abstract] [Full Text] [Related]